Transcription
Welcome to the Stock Market Palunteer channel. Don't miss any new stock insights from us by hitting the subscribe button and feel free to leave your comments. All right, let's check the analysis.
>> Let's just look at the numbers because they are um they're absolutely screaming. In the final week of January 2026, new LS, that's ticker NWLE. It didn't just move, it completely erupted. We watched this thing surge from historical lows of what roughly $1.71 to testing resistance levels north of $2.20. But honestly, the price is secondary to the volume. We saw turnover exceeding the company's entire float multiple times over. So this wasn't a drift. This was a a violent repricing. So the central question we're tackling is whether this volatility is a real fundamental shift driven by IP and a border level coup or if we're all just watching a liquidity event for trapped capital.
I'm arguing this is a validity marker. The new pediatric patent, the arrival of these deal architect directors, it all signals an imminent M&A event. And I uh I come at it from a completely different angle. I see the same numbers. I see the same exact chart, but I see a textbook micro cap volatility trap. When you look under the hood, specifically at the darkpool divergence, the entry of, let's call it, predatory capital like Savvy Management, this looks like a rally engineered to feed the at the market machine. The company is desperate to dilute shareholders to fix a completely broken balance sheet. And this price action is the bait.
Well, I want to get straight into my strategic turnaround thesis because I think the market is just missing the force for the trees here. This isn't just random noise. We are seeing a rational response to three distinct fundamental shifts that all hit in January. First, and you know, most importantly, is the IP moat. On January 6th, the patent for advanced safety design for pediatric extracorporeal therapy hit the wire.
>> Okay. But can we clarify what that actually covers? Because you know patents and medtech are often just they're wall ornaments companies use to justify their R&D spend.
>> No. No. This is far from an ornament. This patent effectively locks down the pediatric niche. We're talking about patients as small as 20 kg and even smaller down to neonates. This is crucial because of something called priming volume. The amount of blood you need to pull out of a body just to fill the machine's tubing. competitors. They literally cannot follow here. If you try to hook a generic diialysis machine up to a baby, the priming volume is so high you'd cause hemodynamic collapse. This patent protects the specific safety designs that allow Newwell to treat these tiny tiny patients. It is a monopoly on the most vulnerable demographic.
>> Economics of that niche later, specifically whether a monopoly on a tiny market is even worth the burn rate. But um go ahead and finish your thought on the fundamentals.
>> Right. So you've got the IP mode, then you have the regulatory tailwind. The CMS reimbursement shift is massive. I mean, historically, hospitals lost money using this device. We went from a financial loss of about $400 per treatment to a contribution margin positive event of over $1,600. That changes the unit economics entirely. It turns the device from a cost center into a profit center for the hospital. But the clincher, the absolute smoking gun for me is the governance overhaul. On January 21st, you don't just remove three directors at once to maintain the status quo. They brought in Mika Graasso and Katherine Field. Grass is from Paulson Investment Company. He isn't a scientist. He's an investment banker. You bring a guy like that in to cut a deal, not to run a lab.
>> That is a compelling narrative. I get it. And I understand why retail investors get excited about bankers on the board. But let's look at the liquidity trap thesis. You see a turnaround. I see a death spiral financial structure. The fundamentals you mentioned, the patent, the reimbursement, they are completely, and I mean completely overshadowed by the company's insolveny. They ended Q3 2025 with $3.1 million in cash. They burned between 2.5 and 3 million a quarter. You do the math. We're in late January. Without this rally to sell stock into, they are technically insolvent right now. The going concern warning in their filings isn't a formality. It is flashing bright red.
>> I'm not ignoring the cash position. Obviously, liquidity is tight, but successful companies raise money all the time, especially when they have news like this.
>> But look at who showed up to the party. On January 20th, Savvy Management filed a 5.41% passive stake in Micro Cap Biotech. Savvy is known as smart money, sure, but definitely not long-term hold money. They are associated with aggressive financing, pipes, volatility arbitrage. Their presence usually signals that a financing event is being structured and likely one that significantly punishes the existing equity holders. And finally, just look at the short squeeze mechanics. We have an 11.58% short interest. When that volume exploded in January, the whole days to cover metric became irrelevant. This move isn't about value. It's about a lack of liquidity forcing shorts to cover into a crowded exit. It's a mechanical squeeze, not a value repricing.
>> That's a fair characterization of the structural risks. I won't deny the short interest plays a role here. But let's dig into the governance forensics because that's where our views really diverge. You mentioned savvy as a negative signal, but I want to focus on Mika Graasso. You simply do not bring in a heavy weight from Pollson investment company unless you are preparing for a sale or a massive fix. Pollson is famous for micro cap syndication and restructuring.
>> Or a massive dilution. Pulson deals often involve very complicated warrant structures that can keep a lid on the stock price for years.
>> But look at the pairing. You have Graasso, the banker, and you have Katherine Field from Halo Collective. Her expertise is specifically in navigating distressed sectors, pivoting business models. This looks like a cleanup crew. They are there to clean up the books, maybe settle liabilities to make the asset palpable for a buyer. If they were just going to dilute and keep the lights on, they could have kept the old board. This specific personnel change signals a transaction. It signals M&A.
>> I'm sorry. I just don't buy that entirely. Grassel's presence implies a financing event is coming first. You can't sell a bankrupt company effectively. You have to recapitalize it to get it across the finish line. And if we are talking about deals, let's look at the one that went completely silent. The Rendiac acquisition. Newella had a letter of intent from August 2025. It's late January 2026. Crickets.
>> Deals take time. You know that especially with crossber assets or complex IP. Not 5 months of silence when you're burning cash like this. If that deal was good, it would have closed. My read is that the new board might be there to kill that deal or liquidate the assets because the due diligence just failed.
>> Or conversely, they're there to raise the funds to actually close it. Remember that rendate deal transforms them from a single product company to a diagnostic plus therapeutic platform. That increases the valuation multiple. But speaking of silence, what about the Dvita pilot?
>> Exactly. Silence is rarely golden in biotech.
>> I see the Dvita partnership as a sleeping giant. Dvita is a massive channel for scale. They dominate kidney care. If that pilot data is good, Newwell becomes an acquisition target for Dvita immediately.
>> But the silence since August 2024 suggests the pilot data was uh equivocal or it failed. If it was a home run, if they were saving lives and cutting costs, we would have seen a press release. You don't sit on good data when you have $3 million in the bank. You shout it from the rooftops. The fact they haven't suggests the new board is dealing with a messy situation, not polishing a gem.
>> Okay, let's pivot to the market mechanics because you brought up the volume. You called it a liquidity trap, but I'm looking at the polyarket correlations. NUW is trading like a high beta proxy for the FDA deregulation theme. We're seeing a 53% chance of the Clarity Act passing in prediction markets right now.
>> So you think this is macro driven?
>> Partially. This stock is moving in lock step with a small cap rotation theme we're seeing in early 2026. It's not just some pump, it's a sector rotation. Investors are looking for assets that benefit from a lighter regulatory touch and Newellis fits that perfectly. If the Clarity Act passes, the path for their pediatric devices becomes even smoother. The market is pricing that in.
>> That's an interesting point. And I track the poly market odds, too. The macro theme is real, sure, but look at the specific micro structure of the stock. I want to talk about the dark pools. On January 23rd, we saw a massive divergence.
>> Define that for someone who isn't staring at level two data all day.
>> Sure. So, lit exchanges are public markets like the NASDAQ. Darkpools are private exchanges for institutions to move large blocks. On the 23rd, the lit exchanges were showing prices ripping above 220, but the darkpool prints, they were lagging, showing massive volume at the bid or lower.
>> Meaning what in your view?
>> Meaning the smart money was using that retail enthusiasm to unload inventory. It's a repellent effect. It suggests institutions were feeding the ducks. They weren't buying the breakout. They were supplying it. And let's not forget the warrant overhang. Series J warrants, Devito warrants, these act as a ceiling.
>> How so?
>> Warrants are just options to buy stock at a fixed price. When the stock spikes above that price, the holders exercise them, get cheap shares, and immediately sell them on the market. It just creates this flood of supply that dampens any real breakout. It's like trying to run uphill with a parachute on.
>> The warrant overhang is a technical ceiling. I agree, but it doesn't negate the underlying asset value. And that brings me to the competitive landscape. This is where the bare thesis just misses the forest for the trees. You're looking at the financial engineering, but look at the actual product. The Aquedex Smartflow is a blue ocean technology.
>> Is it or is it just really expensive?
>> Compare it to the Giants. Look at Baxter International, their Prismax system. Those are doit all machines, CRT, dialysis, but they have massive priming volumes.
>> There's that term again. Why does that matter so much?
>> Okay, imagine a 3 kg infant. They have a total blood volume of maybe 240 mill. A Baxter machine might need 150 to 200 milliliters just to fill the tubing before it even starts. You can't hook a baby up to that. You would drain their body of blood just to prime the pump. you'd cause immediate cardiac arrest. New Ellis has a 33ml circuit. It is the only safe option. That is a moat that Baxter cannot cross without totally redesigning their machine or infringing on these new patents. That's true for the pediatric niche. I won't argue the physics of it, but that market is small. The real money is an adult heart failure. And there you're up against outset medical and the tableau.
>> But tableau is just dialysis. Dialysis reimagined, sure, but it's still diialysis. It relies on diffusion. Aquedex is pure ultrailtration. It solves diuretic resistance where drugs like furicomide fail.
>> Explain that.
>> In heart failure, the kidneys eventually stop responding to water pills. You keep giving the patient drugs, but they stop peeing out the fluid. Their lungs fill up. Aquedex removes salt and water in perfect physiological balance, which dialysis doesn't do with the same precision.
>> Okay, realism check on the standard of care here. The biggest competitor isn't Baxter or Outset. It's a generic drug, IV firosomide. It costs pennies a dose. Aquedex costs thousands per treatment. Hospitals are in a financial crisis. They are going to try the 10-cent drug before they roll in the $1,600 machine, even with the new reimbursement. The economic friction is huge. But that's why the reimbursement shift matters. It changes the hospital's calculation from a loss to a profit. Before they avoided it. Now, with the new code, they actually make a margin. It aligns the clinical incentive with the financial one.
>> Only if they can staff it. You need specialized training to run an Aquedex console. You don't need training to push a plunger on a syringe. And look at the Sea Star medical relationship. Distributing Quellamune sounds great, right? Synergy. Has it generated enough cash to stop the burn? No. David is running out of stones or in this case cash.
>> I admit the cash runway is tight. Less than three months without hitting the ATM. But that urgency is exactly why a deal happens now. Distressed M&A happens when the seller has no other choice.
>> Or why a collapse happens now.
>> Well, the banker and the operator, Grao and Field, they didn't join to oversee a bankruptcy. They join to execute a strategy. The pediatric IP gives them a chip to play that no one else has. That pediatric franchise is a jewel of Baxter or Medronic would want to own to complete their portfolio. And I'm saying the chip might be valuable, but the table fees are too high. To summarize my position, Newuelis is a special situation, absolutely, but it is a dangerous one. I still put the bare thesis at a 40% probability. The cash burn forces them to hit the ATM, which caps the stock. That January rally, a gift to the financeers, Sabbi, the warrant holders, not the retail investor. Until they raise cash, the going concern risk is the only metric that matters.
>> I see why you think that, but let me leave you with the bull thesis. I'll put it at 30% probability, but the asymmetry is just massive. If I'm right, we're looking at a sale of the company leveraging that pediatric IP and the new CMS rates. And the probability of that has never been higher because of the new board. The technology works, and now the banker, Graaso, is at the wheel to monetize it. We aren't hoping for a scientific breakthrough. We're watching a business transaction unfold.
>> Well, on one thing, we can definitely agree. The status quo is over.
>> Absolutely. With less than 3 months of cash runway, Newellis is going to announce either a transformative deal or a massive dilution event in Q1 or Q2 of 2026.
>> It's binary, and the listener has to decide if that $2.20 price tag was an entry point for a buyout or the peak of a squeeze.
>> A fascinating setup either way. That does it for this edition of the debate. Until next time,
>> Thank you for watching the video. Remember to subscribe to the Stock Market Palunteer channel for more stock analysis like this and leave your comments below. See youa.